Skip to main content

Valeo Pharma announces company has filed new drug submission with Health Canada for sabizabulin

Valeo Pharma chief executive Steve Saviuk joined Steve Darling from Proactive to share news the company has been told by Health Canada they have accepted for review Veru’s New Drug Submission (NDS-CV) for sabizabulin for COVID-19.

Saviuk told Proactive Sabizabulin is an antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome and death. The company will now wait to hear back from Health Canada.

Contact Details

Proactive Investors

Stephen Gunnion

+1 604-688-8158

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.